Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07181369 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria

Study acronym: CHILL-MC
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 2 to 3v4
  2. Eligibility criteria expanded, about 52 words
    • Study description expanded, about 8 words
    • Study title expanded, about 1 word
    v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary endpoint revised
    • Start date changed from estimate of Oct 2025 to Oct 6, 2025
    • Site details revised at 2 of 2 sites
    • Study title revised
    • Study description shortened, about 1 word
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a first-in-human study aimed at determining the safety of a single dose of GTX-B001 in healthy participants and in people with chronic inducible urticaria.
Trial Details
NCT Number NCT07181369
Lead Sponsor Granular Therapeutics Limited
Conditions
(from sponsor)		 Healthy Subjects, Cold Urticaria, Symptomatic Dermographism, Chronic Inducible Urticaria
Related terms Chronic Inducible Urticaria, Cold Urticaria, Familial dermographism, Skin Diseases, Urticaria
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov